Diltiazem used as a tacrolimus-sparing agent for treatment of pediatric patients with refractory nephrotic syndrome: a case report and retrospective analysis

Saved in:
Bibliographic Details
Published inEuropean journal of clinical pharmacology Vol. 75; no. 4; pp. 591 - 593
Main Authors Sun, Jie-Yu, Hu, Ya-Hui, Guo, Hong-Li, Jing, Xia, Xu, Ze-Jun, Sun, Fang, Guo, Hui-Lei, Ding, Xuan-Sheng, Chen, Feng, Xu, Jing
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.04.2019
Springer Nature B.V
Subjects
Biomedical and Life Sciences
Biomedicine
Child
Child, Preschool
Cytochrome P-450 CYP3A - genetics
Cytochrome P-450 CYP3A - metabolism
Diltiazem
Diltiazem - pharmacology
Diltiazem - therapeutic use
Drug Interactions
Drug Resistance - genetics
Female
Glucocorticoids - pharmacology
Glucocorticoids - therapeutic use
Humans
Immunosuppressive Agents - pharmacology
Immunosuppressive Agents - therapeutic use
Letter to the Editor
Male
Nephrotic syndrome
Nephrotic Syndrome - diagnosis
Nephrotic Syndrome - drug therapy
Nephrotic Syndrome - pathology
Pharmacology/Toxicology
Retrospective Studies
Tacrolimus
Tacrolimus - pharmacology
Tacrolimus - therapeutic use
Treatment Outcome
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-2
content type line 14
ObjectType-Letter to the Editor-1
ObjectType-Case Study-2
ObjectType-Correspondence-3
content type line 23
ObjectType-Report-1
ISSN:0031-6970
1432-1041
1432-1041
DOI:10.1007/s00228-018-2604-4